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Monoclonal antibody with 
conformational specificity for a 
toxic conformer of amyloid β42 
and its application toward the 
Alzheimer’s disease diagnosis
Kazuma Murakami1, Maki Tokuda1, Takashi Suzuki1, Yumi Irie1, Mizuho Hanaki1, 
Naotaka Izuo2, Yoko Monobe3, Ken-ichi Akagi3, Ryotaro Ishii4, Harutsugu Tatebe4, 
Takahiko Tokuda4,5, Masahiro Maeda6, Toshiaki Kume7, Takahiko Shimizu2 & Kazuhiro Irie1
Amyloid β-protein (Aβ42) oligomerization is an early event in Alzheimer’s disease (AD). Current 
diagnostic methods using sequence-specific antibodies against less toxic fibrillar and monomeric 
Aβ42 run the risk of overdiagnosis. Hence, conformation-specific antibodies against neurotoxic Aβ42 
oligomers have garnered much attention for developing more accurate diagnostics. Antibody 24B3, 
highly specific for the toxic Aβ42 conformer that has a turn at Glu22 and Asp23, recognizes a putative 
Aβ42 dimer, which forms stable and neurotoxic oligomers more potently than the monomer. 24B3 
significantly rescues Aβ42-induced neurotoxicity, whereas sequence-specific antibodies such as 4G8 
and 82E1, which recognizes the N-terminus, do not. The ratio of toxic to total Aβ42 in the cerebrospinal 
fluid of AD patients is significantly higher than in control subjects as measured by sandwich ELISA using 
antibodies 24B3 and 82E1. Thus, 24B3 may be useful for AD diagnosis and therapy.
A hallmark of Alzheimer’s disease (AD) is amyloid deposition in senile plaques that consist mainly of 40- and 
42-residue amyloid β -proteins (Aβ 40 and Aβ 42)1. These proteins are generated from Aβ -protein precursor by 
two proteases, β - and  γ -secretases. Aβ aggregates (oligomerizes) through intermolecular β -sheet formation to 
exhibit neurotoxicity. The term “aggregation” in this context is defined as the change from Aβ monomers into 
amyloid fibrils via oligomers or protofibrils. Aβ 42 plays a more important role in AD pathogenesis than Aβ 40 
because of its stronger ability to aggregate and show neurotoxicity2. Multiple lines of evidence have proposed that 
the soluble oligomeric assembly of Aβ is more exclusively involved in neuronal death and cognitive impairment 
than its insoluble fibrils and protofibrils3. The minimal unit of these oligomers, which have been divided into low 
molecular-weight oligomers (2–12-mer) and high molecular-weight oligomers (24–100-mer), is thought to be 
either a dimer4 or trimer5 (2 or 3 × n-mer). Aβ oligomer accumulation is among the earliest phenomena during 
the progression of AD pathology compared with other AD-related events such as hyperphosphorylation of tau 
protein, decreased hippocampal volume, and lowered glucose metabolism6. These highlight the significance of 
early and accurate diagnosis by targeting Aβ oligomer.
We have previously reported using solid-state NMR7 and systematic proline replacement8 that Aβ 42 is held in 
equilibrium of the toxic conformer with a turn at Glu22 and Asp23, and the non-toxic one with a turn at Gly25 
and Ser26 (Fig. 1a). In particular, the proportion of Aβ 42 toxic conformer, in which residues Gln15~Ala21 and 
Val24~Ile32 are involved in forming an intermolecular parallel β -sheet of Aβ 42 aggregates, may contribute to AD 
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pathologies as well as cerebral amyloid angiopathy (CAA) such as Italian mutation7. Moreover, the C-terminal 
hydrophobic core derived from another turn at Gly38 and Val39, in addition to the intramolecular anti-parallel 
β -sheet (Met35~Gly37 and Val40~Ala42), accelerates the aggregation (oligomerization) of Aβ 429. The contribu-
tion of the C-terminal turn structure to the superior ability of Aβ 42 to form oligomers has also been reported 
by other groups10–12. Based on this knowledge, we have proposed a dimer model of Aβ 42 with the “toxic turn” at 
Glu22 and Aps23 and the C-terminal core, which is supposed to be a partial structure of toxic oligomers of Aβ 42 
(Fig. 1b)9.
We previously reported a conformation-targeted monoclonal antibody (11A1)13 against the toxic turn of Aβ 42 
generated by immunization with E22P-Aβ 10–35, a minimum moiety for neurotoxicity including the toxic turn 
as a Pro-X corner (X: variable amino acid residue). 11A1 reacted with intracellular as well as extracellular Aβ 
depositions. In particular, the intracellular accumulation of Aβ could originate preferably from Aβ oligomers in 
AD brains13,14, AD-model mouse brains14,15, and neurons differentiated from induced pluripotent stem cells of 
AD patients16. However, the obvious reactivity of 11A1 with senile plaques (formed by extracellular Aβ accumu-
lation) composed of fibrillar Aβ as well as monomeric Aβ hampers its application towards the diagnosis of AD. 
Indeed, because present diagnoses using sequence-specific antibodies against less-toxic fibrillar and Aβ 42 mono-
mer run a risk of false positives (approximately ~30%) of AD17,18, conformation-specific antibodies targeting neu-
rotoxic Aβ 42 oligomers have garnered much attention for developing more accurate diagnostic methods. Several 
conformation-specific antibodies such as anti-prefibrillar Aβ oligomers (OC)19, and anti-Aβ 42-derived diffusible 
ligands (ADDLs) antibodies have been applied to AD diagnosis using cerebrospinal fluid (CSF). Although these 
attempts were likely successful in the limited cohort, almost all the target molecules of these antibodies could be 
Aβ oligomers that move into the fibrillar stage (on-pathway)20, so the possibility of false positives in the future 
trials using these antibodies cannot be excluded. Therefore, the development of monoclonal antibodies that spe-
cifically recognize toxic Aβ oligomers that exist as stable soluble intermediates (off-pathway) is an important 
challenge for selectively removing neurotoxic Aβ oligomers.
In this paper, we report a novel monoclonal antibody (named as 24B3) with greatly enhanced selectivity for 
the toxic Aβ 42 conformer compared with 11A1, the first generation conformation-targeted antibody. Here, we 
describe the characterization of 24B3 by physicochemical and biochemical analyses. Notably, 24B3 recognizes 
the toxic oligomer model of Aβ 42 (Fig. 1b) more preferentially than the corresponding monomer. Furthermore, 
24B3 was applied to the diagnosis of AD using human CSF, as determined by a novel sandwich enzyme-linked 
immunosorbent assay (ELISA) that uses a combination of 24B3 and an anti-N-terminus-specific antibody, 82E1.
Figure 1. Development of antibody 24B3 that specifically recognizes a toxic conformer of Aβ42 with a turn 
at Glu22 and Asp23. (a) Aβ 42 is held in equilibrium of the toxic conformer (right) with turn at positions 22 
and 23, and the non-toxic one (left) with turn at positions 25 and 26. The proportion of toxic conformer of Aβ 
42 could be enhanced by E22P or E22K mutations7. (b) Dimerization of the toxic Aβ 42 conformer that has a 
turn at Glu22 and Asp23 to induce close interaction between Tyr10 and Met35 for formation of the S-oxidized 
radical cation of Met35 and a C-terminal hydrophobic core for stabilization of radicals for long-lasting oxidative 
stress. Based on this hypothesis, a toxic oligomer model of Aβ 42 covalently cross-linked using L,L-DAP at Val40 
was designed. (c) Enzyme immunoassay using 24B3 and 11A1 (15, 30, 60, 120 ng/mL) to detect Aβ 42 mutants 
(2.5 μ g/well) substituted with proline at Glu22, Gly33, Leu34, Val36, Gly37, Gly38, Val39, Val40, and Ile41 
together with Aβ 40, Aβ 42, and E22V-Aβ 42, coated on plates.
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Results
Development of antibody 24B3 that specifically recognizes the toxic conformer of Aβ42. To 
generate the antibody that specifically recognizes the “toxic turn” at Glu22 and Asp23 of Aβ 42, the seven mono-
clones previously selected using E22P-Aβ 10–3513 containing the toxic turn were re-evaluated in detail based on 
their ability to react with various Aβ 42 mutants with a proline replacement mainly at C-terminal region8. In order 
to precisely evaluate the selectivity for toxic conformer of Aβ 42, the concentration of clones used in this re-eval-
uation (15~120 ng/mL) was lower than that of the previous study13 (125~1,000 ng/mL). Enzyme immunoassay 
(EIA) identified a unique clone, named 24B3, as showing the strongest immunoreactivity with E22P-Aβ 42 among 
the other mutants in a dose-dependent manner (Fig. 1c). The specificity of 24B3 for E22P-Aβ 42 was much higher 
than that of 11A1. Moreover, 24B3 barely bound to E22V-Aβ 42, in which valine is known as a turn breaker, while 
11A1 reacted weakly with E22V-Aβ 42 (Fig. 1c). These results suggest that 24B3 is more conformation-specific 
for the toxic Aβ 42 conformer compared with 11A1 since the proportion of toxic conformer of Aβ 42 could be 
enhanced by E22P mutation.
Prevention of Aβ42-induced neurotoxicity by 24B3 occurs through sequestration of Aβ42 
oligomers. To determine the effects of 24B3 on Aβ 42-induced neurotoxicity, we performed the MTT assay 
on SH-SY5Y human neuroblastoma cells, a neuronal cell culture model. Not only 24B3 but also 11A1 signifi-
cantly rescued the neurotoxicity induced by both Aβ 42 and E22P-Aβ 42 as a toxic conformer surrogate8, whereas 
neither 4G8 nor 82E1 (anti-N-terminus of Aβ 42) could rescue (Fig. 2a,b). Notably, the protective effects of 24B3 
were slightly higher than that of 11A1. All of these antibodies did not affect cell viability (Fig. 2c). Because we 
previously reported the neuroprotective potential of 11A1 on rat primary neurons21, the additional experi-
ments were carried out. We then obtained similar results using primary neuronal cultures originated from rat 
(Supplementary Fig. 1). The slight inhibition of cytotoxicity by 11A1 was also observed with PC12 cells13. These 
observations are consistent with previous findings that A11 rescues Aβ 42-induced toxicity in SH-SY5Y cells, 
whereas 6E10 does not22, raising the possibility that 24B3 may target the oligomeric species of Aβ responsible for 
neurotoxicity in a manner similar to A11 although the haptens of these antibodies are different from each other. 
These results suggest that conformation-specific antibodies may be more beneficial in treating AD pathology than 
Figure 2. Prevention of Aβ42-induced neurotoxicity by sequestering Aβ42 oligomer using 24B3. (a,b) 
Neurotoxicity of (a) Aβ 42 and (b) E22P-Aβ 42 (1 μ M) on SH-SY5Y cells, and effects of IgG, 82E1, 4G8, 11A1, 
and 24B3 (0.1 mg/mL) on Aβ -induced neurotoxicity after 48 h incubation, determined by MTT assay. (c) Effects 
of antibodies alone on the cell viability. #p < 0.05 vs vehicle alone, * p < 0.05. Data are expressed as mean ± s.e.m. 
(n = 3). (d,e) Dot blotting for Aβ 42 and E22P-Aβ 42 using 24B3 and 4G8 for detection. Aβ solution (25 μ M) 
was incubated for the indicated duration at 37 °C, and 1 μ L of solution was spotted on the membrane at each 
time point. (d) Representative blots and (e) densitometric quantifications of immunoblot signals from triplicate 
samples are shown in (d), respectively. ● , 24B3 for Aβ 42; ○ , 24B3 for E22P-Aβ 42; ▲ , 4G8 for Aβ 42; △ , 4G8 for 
E22P-Aβ 42.
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sequence-specific antibodies, and that Aβ aggregates sequestered by 24B3 may contain oligomers formed by the 
toxic Aβ 42 conformer.
Since both Aβ 42 and E22P-Aβ 42 induced neurotoxicity in a time-dependent manner21, we determined by dot 
blotting how 24B3 detects the toxic conformer of Aβ 42. Regarding the immunoreactivity of 24B3, the relative 
intensity of E22P-Aβ 42 gradually increased to a maximum after 4 h of incubation, whereas Aβ 42 reacted more 
slowly than E22P-Aβ 42 (Fig. 2d,e). It should be noted that the relative quantification of reactivity of 24B3 against 
Aβ 42 was carried out under the longer exposure of blots due to its moderate affinity. It is noteworthy that the 
potent immunosignal of E22P-Aβ 42 against 24B3 immediately after dissolution means more rapid formation of 
the toxic conformer by E22P-Aβ 42 compared with Aβ 42. In contrast, the relative intensity by 4G8 against Aβ 42 
was potent even after 0 h of incubation, and it remained almost constant up to 24 h (Fig. 2d,e). Under the longer 
exposure in the case of E22P-Aβ 42 treated with 4G8 because of its weak affinity, the similar results to Aβ 42 treated 
with 4G8 were obtained (Fig. 2d,e). These results suggest that the Aβ 42 oligomers responsible for neurotoxicity 
can be attributed to those detected by 24B3, but not those detected by 4G8.
Synthesis and characterization of the E22P-Aβ42 dimer as a toxic oligomer surrogate. We 
recently validated optically active L,L-diaminopimelic acid (DAP)23 as a useful linker near the intermolecular 
β -sheet region (Ala30) of E22P-Aβ 4024. This strategy was applied to the synthesis of the E22P-Aβ 42 dimer as a 
toxic oligomer model for Aβ 42. The E22P mutation not only enhanced the neurotoxicity of Aβ 42 ~10-fold25, but 
also increased the ratio of toxic conformation of Aβ 427. According to our proposed dimer model (Fig. 1b), Val40 
in the C-terminal hydrophobic core was replaced with the linker. Solid-phase synthesis using Fmoc-L,L-DAP as 
a substitute for Val40 provided a sufficient amount of E22P-Aβ 42 dimer (Fig. 1b) with high purity (6.0% yield, 
> 98% purity, Supplementary Fig. 2).
The aggregative ability of the E22P-Aβ 42 dimer with a covalent linker at Val40 was evaluated using 
thioflavin-T (Th-T), a reagent that fluoresces when bound to Aβ aggregates, and transmission electron micros-
copy (TEM). E22P-Aβ 42 aggregated with a lag time of ~4 h and a maximum fluorescence value after being incu-
bated for 96 h (Fig. 3a), and its velocity for aggregation was higher than that of Aβ 42, as previously reported25. 
In contrast, the fluorescence of the E22P-Aβ 42 dimer remained almost unchanged even after a 96 h incubation 
(Fig. 3a). Given the moderate increase in the fluorescence after incubation for 168 and 336 h, these time-point 
samples were subjected to TEM analysis. As shown in Fig. 3b, we observed short and globular aggregates 
(oligomers) predominantly in the E22P-Aβ 42 dimer, unlike the typical fibrils found in E22P-Aβ 42.
Moreover, circular dichroism (CD) spectrometry was measured to analyze the secondary structure of the 
E22P-Aβ 42 dimer. A positive peak at ~190 nm and a negative peak at ~210 nm began to increase gradually after 
dissolution, suggesting that a random structure transformed into a β -sheet architecture in the E22P-Aβ 42 dimer 
in a manner similar to E22P-Aβ 42 (Fig. 3c).
The ability of the E22P-Aβ 42 dimer to form oligomers was further studied using size exclusion chromatog-
raphy. As a control reference, the peaks corresponding to the monomer of E22P-Aβ 42 and its 6~8-mer were 
observed immediately after dissolution, but these peaks disappeared almost completely after 1 h incubation 
(Fig. 3d). This observation suggests the formation of insoluble fibrillar aggregates of E22P-Aβ 42, as observed in 
Fig. 3b. In contrast, the E22P-Aβ 42 dimer formed stable oligomers (comprising 6~8-mers) during incubation 
for ~24 h even after dissolution (Fig. 3d). It should be noted that the peak of E22P-Aβ 42 dimer did not appear to 
be observed even at the initial time point (Fig. 3d). Actually, we confirmed the presence of E22P-Aβ 42 dimer in 
reverse-phase HPLC on ODS column (Supplementary Fig. 2b). Once dissolved in the PBS solution, the E22P-Aβ 42 
dimer could intrinsically form stable oligomers during elution in size exclusion chromatography. Alternatively, 
in the size exclusion chromatography using Superdex75 10/300GL column, E22P-Aβ 42 dimer itself might not be 
able to give a sharp peak because of adopting various conformations. Similar phenomena were also observed in 
Aβ 42 monomer using reverse-phase HPLC on ODS column under the acidic condition; Aβ 42 was observed only 
as a broad peak26.
The neurotoxicity of the E22P-Aβ 42 dimer was measured using the MTT assay on human neuroblastoma 
SH-SY5Y cells. After being incubated for 16 h when the stable oligomer of the E22P-Aβ 42 dimer is suspected to be 
predominant, the viability of cells treated with the E22P-Aβ 42 dimer was lower than that of E22P-Aβ 42 at 1~10 μ M, 
indicating that the E22P-Aβ 42 dimer is more neurotoxic than E22P-Aβ 42 (Fig. 3e). Overall, the E22P-Aβ 42 dimer 
can form stable oligomers with a β -sheet structure, suggesting that the E22P-Aβ 42 dimer is a suitable model for 
studying toxic Aβ 42 oligomers. However, additional oligomer models such as trimer or tetramer should be exam-
ined to conclude which oligomeric species are toxic.
Binding affinity of 24B3 for the E22P-Aβ42 dimer. To investigate the potential of 24B3 to recognize 
toxic Aβ 42 oligomers, we performed an EIA test. 24B3 showed stronger immunoreactivity against the E22P-Aβ 42 
dimer than E22P-Aβ 42; its specificity for the E22P-Aβ 42 dimer was much higher than that of 11A1 (Fig. 4a,b). In 
contrast, the relative affinity of 4G8 for the E22P-Aβ 42 dimer was weak (Fig. 4c).
Surface plasmon resonance (SPR) was employed to evaluate the binding constant of 24B3 for Aβ , in which Aβ 
was immobilized on a sensor chip based on a biotin-streptavidin interaction. The biotinylation of Aβ 42, E22P-Aβ 42, 
and the E22P-Aβ 42 dimer did not affect their aggregation profiles and neurotoxicity, respectively (Fig. 3a, 
Supplementary Fig. 3). 24B3 bound 6.5-fold more strongly to the E22P-Aβ 42 dimer (KD = 1.8 nM) than 11A1 
(KD = 10 nM) (Table 1, Supplementary Fig. 4). In addition, consistent with the EIA test (Fig. 4a,b), the binding 
affinity of 24B3 for E22P-Aβ 42 (KD = 3.1 nM) was ~8-fold higher than that of 11A1 for E22P-Aβ 42 (KD = 24 nM). 
Taken together with the lower binding affinity of 24B3 than 11A1 for Aβ 42 (24B3: KD > 100 nM, 11A1: KD 15 nM), 
these results strongly suggest that 24B3 specifically recognizes toxic oligomers of Aβ rather than monomeric Aβ .
www.nature.com/scientificreports/
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Figure 3. The E22P-Aβ42 dimer forms stable 6~8-mer associated with neurotoxicity. (a) Th-T assay result 
for each Aβ (25 μ M) after incubation for the indicated duration at 37 °C. ● , the E22P-Aβ 42 dimer; ○ , the 
biotinylated E22P-Aβ 42 dimer; ▲ , E22P-Aβ 42; △ , biotinylated E22P-Aβ 42. Data are expressed as mean ± s.e.m. 
(n = 8). (b) TEM analysis of Aβ aggregates formed from E22P-Aβ 42 and E22P-Aβ 42 dimer after incubation for 
the indicated duration at 37 °C. Arrowheads indicate oligomers. Scale bar = 50 nm. Upper, E22P-Aβ 42; lower, 
the E22P-Aβ 42 dimer. (c) Analysis of secondary structure of E22P-Aβ 42 and the E22P-Aβ 42 dimer (25 μ M) 
after incubation for the indicated duration at 37 °C using CD spectrometry. (d) The ability of E22P-Aβ 42 and 
E22P-Aβ 42 dimer (25 μ M) to form soluble oligomers was evaluated by size exclusion chromatography after 
incubation for the indicated duration at 37 °C. The peptide was detected by absorbance at 220 nm. Molecular 
marker sizes are shown in kDa. V0: void volume. (e) The viability of SH-SY5Y cells treated with either E22P-Aβ 
42 or E22P-Aβ 42 dimer at the indicated concentration at 37 °C for 16 h. Data are expressed as the mean ± s.e.m. 
(n = 3). Absorbance obtained after adding vehicle (Veh: 0.1% NH4OH) was taken as 100%. #p < 0.05 vs vehicle 
alone, * p < 0.05.
Figure 4. Specific recognition of E22P-Aβ42 dimer by 24B3. Enzyme immunoassay using (a) 24B3, (b) 11A1, 
and (c) 4G8 (15~120 ng/mL) to detect Aβ 42, E22P-Aβ 42, and the E22P-Aβ 42 dimer (2.5 μ g/well) coated on 
plates.
www.nature.com/scientificreports/
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Ratio of toxic conformer to total Aβ42 as a potential biomarker for AD pathology in CSF. It is 
becoming important to identify and validate biomarkers in biological fluids for AD diagnosis, especially for pre-
diction of patients with mild cognitive impairment (MCI) who will convert to AD. Given the potential of 24B3 
as a specific probe for toxic Aβ 42 oligomers, we developed a novel sandwich ELISA using a combination of 
anti-N-terminus antibody (82E1) for capture and 24B3 conjugated with horseradish peroxidase for detection. 
To determine if the ratio of toxic conformer to total Aβ 42 is correlated with the AD pathology in the brain7, we 
performed ELISA on human CSF samples from 13 patients with AD/MCI and 12 age-matched controls (Table 2); 
we combined the patients with MCI and those with AD to compare with the age-matched controls, since all the 
MCI patients in this study were those with “MCI due to AD”27. Accordingly, the ratio of toxic conformer to total 
Aβ 42 in AD/MCI patients was significantly higher than that in the age-matched controls (p = 0.0135, Fig. 5a). 
In contrast, the difference in total Aβ 42 as one of the conventional biomarkers28 was not significant (p = 0.0863, 
Fig. 5c). Intriguingly, the absence of a significant difference in the amount of toxic Aβ 42 conformer between AD/
MCI and control groups (p = 0.4620, Fig. 5b) might be due to the disappearance of toxic oligomers by moving 
onto fibrillization of Aβ 42 monomer. Indeed, the reduction of Aβ 42 levels in CSF are originated from plaque 
formation by enhanced aggregation in the cerebral parenchyma as well as the disturbed clearance of Aβ from the 
cerebral parenchyma into CSF28. These results signify the proportion of toxic conformer of Aβ 42 rather than its 
amounts. Considering its potential inaccuracy when to judge the diagnosis based on only the amount of total Aβ 
4217,18, the ratio of toxic conformer of Aβ 42 to total Aβ 42 could be a better substitute for precise diagnosis of AD.
Antibody Immobilized Aβ ka (M−1 s−1) kd (s−1) KD (nM)
24B3
Aβ 42 > 5.0 × 102 5.0 × 10−5 > 100
E22P-Aβ 42 2.3 (0.015)* × 105 7.2 (0.12) × 10−4 3.1a** (0.072)
E22P-Aβ 42 dimer 2.3 (0.017) × 105 4.2 (0.25) × 10−4 1.8b (0.092)
11A1
Aβ 42 3.3 (0.12) × 104 4.8 (0.23) × 10−4 15c (0.93)
E22P-Aβ 42 4.0 (0.040) × 104 9.5 (0.27) × 10−4 24d (0.81)
E22P-Aβ 42 dimer 9.2 (0.98) × 102 9.4 (1.6) × 10−6 10e (0.94)
Table 1.  Dissociation constant (KD) together with association (ka) and dissociation (kd) rate constants of 
24B3 and 11A1 for Aβ derivatives. * The values in the parentheses indicate standard deviation from triplicate 
experiments. * * The different letters show significant differences.
Case Age Sex MMSE Clinical diagnosis
1 68 M 24 AD
2 69 F 18 AD
3 77 F 21 AD
4 82 F 18 AD
5 75 F 18 MCI
6 84 F 21 MCI
7 78 M 13 AD
8 81 M 23 MCI
9 75 M N/A AD
10 82 F 23 MCI
11 84 M 22 AD
12 68 M 20 AD
13 79 F 28 MCI
14 58 M Control
15 73 F Control
16 70 F Control
17 71 F Control
18 68 F Control
19 81 F Control
20 77 F Control
21 69 F Control
22 71 F Control
23 77 M Control
24 78 M Control
25 74 M Control
Table 2.  Summary of clinical diagnosis and mental state*. * MMSE, mini-mental state examination; AD, 
Alzheimer’s disease; MCI, mild cognitive impairment; N/A, not available.
www.nature.com/scientificreports/
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Discussion
Immunotherapy-mediated removal of Aβ aggregates is one of the first disease-modifying therapies for AD. 
However, several anti-Aβ antibodies recently tested in clinical trials failed29, possibly because they were evaluated 
in later stage AD patients, when neuronal cells have been irreversibly damaged. In this stage, the elimination of 
Aβ 42 oligomers is no longer beneficial. Several ongoing immunotherapy trials involving patients diagnosed with 
preclinical AD or who carry a genetic mutation that induces AD symptoms may be more successful.
Our ideas are based on the concept that selective removal of toxic Aβ oligomers is important in immuno-
therapy since non-toxic Aβ plays a physiologically important role in synapse communication30 and regulation of 
glucose metabolism31. We developed the conformation-specific monoclonal antibody 24B3, which specifically 
recognizes the toxic conformer of Aβ 42 in toxic oligomers (Fig. 4), and demonstrated a correlation between the 
ratio of toxic conformer to total Aβ 42 and the pathology of AD (Fig. 5). Moreover, 24B3 suppressed significantly 
the Aβ -induced cytotoxicity in vitro, while sequence-specific antibodies such as 4G8 with weaker affinity for the 
E22P-Aβ 42 dimer model did not (Figs 2 and 4). Several failures of passive immunization in clinical trials might 
be due to the insufficient affinity of sequence-specific antibodies32 for toxic Aβ 42 conformers. Recent unexpected 
findings on the neuronal hyperactivity induced from immunotherapy using a sequence-specific antibody (3D6) 
reaffirm the significance of confirmation-specific antibody33. Otherwise, they might be ascribed to the unin-
tended elimination of physiologically necessary non-toxic conformers of Aβ 427,34,35, though other reasons such 
as inadequate timing and period to treat with anti-Aβ antibodies have already been proposed36.
E22P-Aβ 42 as a toxic conformer surrogate readily forms toxic oligomers to inhibit long term potentiation 
(LTP)37. Provided that Aβ 42 oligomerization involves the formation of various transient or intransient assemblies, 
which are on- or off-pathway aggregation products, it is indispensable to develop an “off-pathway” Aβ 42 oligomer 
model for developing anti-Aβ drugs with few side effects. To the best of our knowledge, this is the first report on 
the generation and characterization of an Aβ 42 dimer model, which is connected at the C-terminal hydrophobic 
region. Practical synthesis of Aβ dimers has thus far been limited to Aβ 40 dimers4,23,38, partly due to the intrin-
sic and potent ability of Aβ 42 to aggregate during synthesis and preparation. Cross-linkage within this region 
has never been achieved in spite of its significance in oligomerization10–12. Although one study has reported the 
synthesis of a dityrosine cross-linked Aβ 42 dimer at Tyr-1038, its biological activity was not tested due to insuffi-
cient yield. Other oligomer models with high molecular weight such as ADDLs (~24-mer)39 are also considered 
off-pathway aggregates. Dimers, trimers, and tetramers of Aβ 42, as prepared by photo-induced cross-linking of 
unmodified protein (PICUP) technology using 2,2′ -bipyridyl-dichlororuthenium(II) hexahydrate as a catalyst, 
were mainly bound covalently at Tyr1040, although it seems difficult to isolate these oligomers in a pure form. 
Recently, unique synthesis of N-terminal-tethered triple Aβ fragment (Aβ 25–35) has been reported41 as a tri-
meric model, which may be another minimal unit of toxic oligomers (2 or 3 × n-mer) of Aβ 42. When we take 
into account these models as candidates of toxic oligomers, further investigation will be required to clarify the 
significance in vivo, though the pathology of the genetically modified mice to produce Aβ dimer cross-linked at 
Ser8 in N-terminal region was recently reported42.
We identified 24B3 based on the ability to bind the conformer possessing the turn structure at residues 22 and 
23 using some proline-substituted mainly at C-terminal core region mutants of Aβ 42 (Fig. 1). Our findings indi-
cate that 24B3 could be more favorable to the toxic conformer of Aβ 42 with the turn at residues 22 and 23 than 
to 11A1. It should be noted that 11A1 may bind various conformers with turns at other residues, even though 
11A1 is not proline-specific like 24B3. The enhanced reactivity of 24B3 with the E22P-Aβ 42 dimer compared with 
E22P-Aβ 42 (Fig. 4) suggests the stabilization of the toxic Aβ 42 oligomer by formation of the C-terminal core and 
intermolecular β -sheet. Furthermore, the time-dependent reactivity of 24B3 towards Aβ 42 in solution (Fig. 2) 
reflects the amount of toxic Aβ 42 oligomers formed during incubation.
In previously reported sandwich ELISAs for Aβ oligomers43, the same anti-Aβ antibodies were used for both 
capture and detection based on the idea that oligomers have multiple reactive sites. However, it is likely to be diffi-
cult to discriminate toxic Aβ oligomers from less-toxic fibrillar Aβ aggregates using such ELISAs, and their validity 
has thus been questioned44. It is reasonable to use the conformation-specific antibody for detection after captur-
ing total Aβ using 82E1 in sandwich ELISA. Decreased Aβ 42, increased total tau, and increased phosphorylation 
of tau, are currently the most accepted biomarkers for diagnosing AD (probable, possible, or definite AD)28. 
Figure 5. Comparing the ratio of toxic Aβ42 conformer to total Aβ42 in CSF between AD/MCI patients 
and age-matched individuals by sandwich ELISA. ELISA detection results: (a) ratio of toxic conformer of  
Aβ 42 to total Aβ 42, (b) toxic conformer of Aβ 42, and (c) total Aβ 42 in CSF of AD/MCI patients (n = 13) and 
age-matched controls (n = 12).
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There have also been intensive studies on other biomarkers such as Aβ -related or tau-related molecules in order 
to increase diagnostic validity by modifying sensitivity and specificity. However, outliers largely affect the validity 
in these conventional biomarkers, and there have been no studies on the qualitative difference between various 
Aβ conformers in spite of accumulating structural studies of Aβ . Our group proposed the significance of the ratio 
of the toxic conformer to total Aβ 42 in AD pathogenesis7 using solid-state NMR analysis, which demonstrated 
that a ~2-fold increase in the ratio of toxic conformer of E22K-Aβ 42 to wild-type Aβ 42 can in part explain the 
extensive aggregative ability and neurotoxicity of E22K-Aβ 4225. Although the ratio of Aβ 42 to Aβ 40 has been 
suggested as another biomarker45, such a biomarker might correlate more preferably with the amount of senile 
plaque containing less-toxic fibrils rather than with the amount of toxic oligomers.
In summary, the target of a novel conformation-specific monoclonal antibody 24B3 could be oligomers that 
include the toxic conformer of Aβ 42, and the ratio of toxic conformer to total Aβ 42 could be an alternative eval-
uation criterion toward accurate diagnosis of AD. Although the analysis with a larger number of CSF samples is 
indispensable for further validation, the development of a less invasive test using plasma is an attractive goal for 
the future. 24B3 could be promising as a diagnostic tool of AD because of its superior affinity for toxic oligomers 
consisting of toxic conformation of Aβ 42, which is likely to be formed at an earlier stage before AD symptoms. 
Moreover, it could be applied to therapeutics during the early stages of AD.
Methods
Synthesis of biotinylated E22P-Aβ42. Biotin-E22P-Aβ 42 was synthesized in a stepwise fashion on 0.1 
mmol of preloaded Fmoc-L-Ala-PEG-PS resin (Applied Biosystems) by PioneerTM using the Fmoc method, as 
previously described25. Biotin was added as the final residue. Briefly, after the completion of chain elongation 
and cleavage from the resin, the crude peptide was precipitated using diethylether, followed by purification using 
HPLC on Develosil ODS UG-5 column (20 mm i.d. × 150 mm; YMC) with elution at 8.0 mL/min by an 80 min 
linear gradient of 10–50% CH3CN containing 0.1% NH4OH. Lyophilization yielded a pure peptide, the purity of 
which was confirmed by HPLC (> 98%, 9.9% yield). The molecular weight of biotin-E22P-Aβ 42 was confirmed 
by liquid chromatography-mass spectrometry, followed by deconvolution (LC-MS; Acquity UPLC system H-class 
with Xevo G2-S, Waters); m/z, calculated: 4709.44; observed: 4708.95 [MH]+ (Supplementary Fig. 2a).
Synthesis of the E22P-Aβ42 dimer and its biotinylated derivative. Fmoc-L,L-DAP was either 
synthesized as described previously24 or purchased from Sigma. The E22P-Aβ 42 dimer (Fig. 1b) or the 
biotin-E22P-Aβ 42 dimer was synthesized as basically described above, except that a pseudoproline dipeptide, 
Fmoc-Gly-L-Ser(ψ Me,Mepro)-OH (Novabiochem), was utilized at the positions Gly25 and Ser26. Val40 was 
replaced with L,L-DAP as a cross linker. Regarding the E22P-Aβ 42 dimer, the purification using HPLC on 
YMC-Pack ODS-A column (20 mm i.d. × 150 mm; YMC) with elution at 8.0 mL/min by a 70 min linear gradi-
ent of 20–60% CH3CN containing 0.1% trifluoroacetic acid was carried out. Subsequent purification was per-
formed using a YMC-Pack PROTEIN RP column (20 mm i.d. × 150 mm; YMC) with elution at 8.0 mL/min by 
an 80 min linear gradient of 20–60% CH3CN containing 0.1% trifluoroacetic acid. Lyophilization gave a pure 
peptide, the purity of which was confirmed by HPLC (> 98%, 6.0% yield). The molecular weight of the E22P-Aβ 
42 dimer was confirmed by LC-MS, followed by deconvolution; m/z, calculated: 8920.16; observed: 8920.29 [M]+ 
(Supplementary Fig. 2b).
Regarding the biotin-E22P-Aβ 42 dimer, the purification using HPLC on YMC-Pack ODS-A column (20 mm 
i.d. × 150 mm; YMC) with elution at 8.0 mL/min by an 80 min curve gradient (curve 7 in Waters M600 sys-
tem) of 30–60% CH3CN containing 0.1% trifluoroacetic acid was carried out. Subsequent purification was per-
formed using an XBridge BEH C18 Prep column (19 mm i.d. × 150 mm; Waters) with elution at 8.0 mL/min by 
an 80 min linear gradient of 10–50% CH3CN containing 0.1% NH4OH. Lyophilization gave a pure peptide, the 
purity of which was confirmed by HPLC (> 98%, 3.4% yield). The molecular weight of the biotin-E22P-Aβ 42 
dimer was confirmed by LC-MS, followed by deconvolution; m/z, calculated: 9372.78; observed: 9372.92 [M]+ 
(Supplementary Fig. 2c).
HFIP treatment of Aβ. For treatment with 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Wako), each Aβ was 
dissolved in HFIP at 1 mg/mL. After incubation at room temperature for 30 min, the solution was sonicated for 
5 min, and dried in vacuo. The resultant film of Aβ was stored at − 80 °C until use.
Thioflavin-T (Th-T) assay. The aggregative ability of each Aβ was evaluated with a previously described 
thioflavin-T (Th-T; Sigma) fluorescence assay25. Aβ was dissolved in 0.1% NH4OH at 250 μ M, followed by 10-fold 
dilution with phosphate buffered saline (PBS; 50 mM sodium phosphate, and 100 mM NaCl, pH 7.4) to a final 
concentration of 25 μ M. After incubating at 37 °C for the desired period, 2.5 μ L of the reaction solution was added 
to 250 μ L of 5.0 μ M Th-T in 5.0 mM Gly-NaOH (pH 8.5), followed by the measurement of fluorescence at 430 nm 
excitation and 485 nm emission using a microplate reader (Fluoroskan Ascent; Thermo Scientific).
Transmission electron microscopy (TEM). The Aβ aggregates after incubation for the desired period in 
the Th-T assay were examined under a H-7650 electron microscope (Hitachi). The experimental procedure has 
been described elsewhere25. After the supernatant was removed from the pellets, the resultant aggregates were then 
suspended in water (100 μ L) by gentle vortex mixing, and centrifuged at 6,600 rpm for 1 min. These suspensions 
were applied to a 200 mesh Formvar-coated copper grid (Nissin EM), and allowed to dry in air for 5 min after being 
negatively stained for several seconds with 2% uranyl acetate and subsequently subjected to microscopy.
Circular dichroism (CD) spectrometry. The secondary structure of the Aβ dimer was estimated by CD 
spectrometry (J-805; JASCO) using a 0.1 mm quartz cell, as described elsewhere37. The Aβ solution (25 μ M) 
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prepared above was incubated at 37 °C. An aliquot was loaded into the quartz cell, and CD spectra were recorded 
at 190–260 nm. The spectra of Aβ are shown after subtraction of the spectrum for the vehicle alone.
Size exclusion chromatography. The Aβ solution (25 μ M) was incubated at 37 °C. After the solution was 
collected periodically and centrifuged at 17,860 × g at 4 °C for 10 min, the supernatant was analyzed by size exclu-
sion chromatography on the Superdex75 10/300GL column (10 mm i.d. × 300 mm; GE Healthcare) with elution 
at 0.6 mL/min by filtered- and degassed-PBS (pH 7.4), attached to a Waters LC system with a 2489 UV/Visible 
detector and 1525 binary HPLC pump controlled by EmpowerTM3 software (Waters), as described elsewhere24. 
The peptide was detected by absorbance at 220 nm. Calibration curves of size exclusion columns were constructed 
using dextran standards (Mp: mean peak molecular weight, 43500, 21400, 9890, 4440) (Sigma) together with Blur 
dextran 2000 (GE Healthcare) as an indicator of the void volume (V0).
MTT assay on SH-SY5Y cells. Human neuroblastoma, SH-SY5Y cells, maintained in a 1:1 mixture of 
Eagle’s minimum essential medium (Wako) and Ham’s F12 medium (Wako) containing 10% fetal bovine serum 
(Biological Industries), were used as a neuronal cell model to estimate the neurotoxicity of each Aβ with a slight 
modification to the previously described method24. In brief, each Aβ was dissolved in 0.1% NH4OH to generate a 
10X stock solution. The resultant peptide solution (10 μ L) was diluted with 0.1% NH4OH to appropriate final con-
centrations in medium before being added to 100 μ L of the culture medium of near-confluent cells (104 cells/well) 
after one or two overnight incubation. In the case to test the effect of antibodies on the cells, the culture medium 
was replaced with fresh medium containing pre-incubated (30 min) Aβ solution with antibodies. After being 
treated at 37 °C for 16 or 48 h, 10 μ L of 5 mg/mL MTT (Sigma) was added to cells, followed by incubation for 4 h 
at 37 °C. After removing the medium, 100 μ L cell lysis buffer (10% SDS, 0.01 M NH4Cl) was subsequently added 
to the cells. The resulting cell lysate was subsequently incubated overnight in the dark at room temperature before 
absorbance measurements were made at 595 nm with a microplate reader (MultiScan JX; Thermo Scientific). 
Absorbance obtained by the addition of vehicle (0.1% NH4OH) was taken as 100%.
MTT assay on rat primary neurons. Animals were treated in accordance with guidelines by the Kyoto 
University Animal Experimentation Committee and guidelines by The Japanese Pharmacological Society. This 
study was approved by Kyoto University Animal Experimentation Committee. Neuronal cultures were obtained 
from the cerebral cortices of fetal Wistar rats (Nihon SLC) at 17–19 days of gestation as described previously21. 
Cultures were maintained in Neurobasal medium with 2% B-27 supplement, 25 μ M sodium glutamate, and 
0.5 mM L-glutamine at 37 °C in a humidified atmosphere of 5% CO2. After 4 days in culture, medium was 
replaced with sodium glutamate-free Neurobasal medium. Only mature cultures (8~12 days in vitro) were used 
for the experiments. In all experiments, B-27 supplement without antioxidants was utilized during the treatment 
of Aβ 42 as described previously21.
Neurotoxicity was assessed by MTT assay according to the previously reported protocol21. After 30 min of 
pre-incubation on ice for Aβ 42 solution (10 μ M) in 0.1% NH4OH, followed by 10-fold dilution with Neurobasal 
medium, the medium containing Aβ was added to the cell culture for replacement. After incubation of Aβ 42 at 
37 °C for 96 h, the culture medium was replaced with medium containing 0.5 mg/mL MTT, and cells were incu-
bated for 30 min at 37 °C. 2-Propanol was added to lyse the cells, and absorbance was measured at 595 nm with 
an absorption spectrometer (microplate reader model 680, Bio-rad). The medium of vehicle treatment for each 
experiment contained 0.01% NH4OH. The absorbance obtained by the addition of vehicle (0.1% NH4OH) was 
taken as 100%.
Enzyme immunoassay (EIA). A 96-well Maxisorp plate (Nunc) was incubated with each Aβ (2.5 μ g/well) 
dissolved in 50 mM sodium carbonate for 2 h at room temperature, followed by treatment for blocking with 
5% bovine serum albumin at 4 °C overnight, as described previously13. Briefly, after incubation with each 
clone obtained in the previous work13 for 1 h at room temperature, the plate was treated with a horseradish 
peroxidase-coupled anti-mouse IgG antibody (IBL), and quantified using o-phenylenediamine dihydrochloride 
substrate (Sigma) before measurements at 492 nm with a microplate reader (MultiScan JX; Thermo Scientific).
Surface plasmon resonance (SPR). Binding affinity tests were performed using a BIAcore X100 biosensor 
(GE Healthcare), as previously described13. In brief, sensor chip SA, to which streptavidin was anchored, was pre-
conditioned by running HBS-EP buffer (GE Healthcare). Each HFIP-treated biotinylated Aβ dissolved in HBS-EP 
buffer (1 nM) was immobilized on the chip according to the manufacturer’s protocol. The antibody was dissolved 
in HBS-EP buffer and injected over the chip-immobilized Aβ at a flow rate of 5 μ L/min. Either 20 mM Gly-HCl 
buffer (pH 2.0) or 5 M guanidine hydrochloride was used as the regeneration buffer. The values of response units 
(RU) obtained from a sample cell minus the RU obtained from a reference cell were used for analysis. Association 
and dissociation data were collected with flowing running buffer for 180 s and 360 s, respectively. The association 
and dissociation rate constants, and dissociation constant (ka, kd, and KD) were calculated using a serial dilution 
series of antibody concentrations according to BIAevaluation 3.1 software (GE Healthcare).
Dot blotting. One microliter of each Aβ solution (25 μ M) was applied to a nitrocellulose membrane after 
incubation at 37 °C (0.2 μ m pore size; Bio-rad) as previously described21. After blocking in 5% non-fat milk dis-
solved in Tris-buffered saline containing 0.1% Tween-20 overnight at 4 °C, the membrane was treated with 24B3 
or 4G8 (0.5 μ g/mL) for 1 h at room temperature before being incubated with secondary antibody. Development 
was performed with enhanced chemiluminescence and quantified using LAS-4000 (Fujifilm). ImageJ 1.42 (NIH) 
software was used to quantify the blots.
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Subjects and collection of CSF samples. This study was conducted in accordance with the principles of 
Helsinki Declaration. The study was approved by the University Ethics Committee of Kyoto Prefectural University 
of Medicine. All subjects provided written informed consent to participate in the study. We collected CSF samples 
from 13 patients [aged 68~84 (mean ± SD, 77.1 ± 5.6) yr] with clinically diagnosed AD (n = 8) or MCI (n = 5), 
and 12 age-matched control subjects [aged 61~84 (mean ± SD, 72.3 ± 5.8) yr; see Table 2 for characteristics of 
study participants]. At the time of diagnosis, a full clinical history was taken, and physical and neurological exam-
inations, Mini-Mental State Examination (MMSE), routine blood analyses, and magnetic resonance imaging 
(MRI) of the brain were performed for all subjects. The patients with AD met the criteria for probable AD defined 
in the diagnostic and research criteria established by the National Institute on Aging (NIA) and the Alzheimer’s 
Association (AA)46. All MCI patients were non-demented, not fulfilling the criteria for probable AD dementia46, 
but met the criteria of “MCI due to AD” defined by NIA and AA27. There were no significant differences in age 
between the AD/MCI group and the control group. None of the control subjects had memory complaints or any 
other cognitive symptoms.
Fresh CSF samples were obtained from the enrolled subjects and then immediately stored at − 80 °C until 
used for immunoassays. All lumbar punctures were performed in the early morning to exclude the effects of daily 
fluctuation in the levels of Aβ in CSF47.
Enzyme-linked immunosorbent assay (ELISA). Microtiter plates (96 wells) were coated with 100 μ L/well 
of 50 mM sodium carbonate containing 82E1 (IBL) and allowed to adhere overnight at 4 °C. Plates were washed 
with PBS and blocked for overnight at 4 °C with 200 μ L/well of 1% (w/v) bovine serum albumin in PBS containing 
0.05% NaN3. After two washes with PBS containing 0.02% Tween-20 (PBS-T), 100 μ L of CSF was serially diluted 
in 1% bovine serum albumin in PBS-T before being added in triplicate to wells before incubation overnight at 
4 °C. After four washes with PBS-T, each well was treated with 100 μ L of horseradish peroxidase-conjugated 24B3 
for 1 h at 4 °C. ELISA signals were detected by chemiluminescence using an enhanced chemiluminescent sub-
strate (SuperSignal ELISA Femto Maximum Sensitivity, Thermo Scientific), and then measured with a microplate 
luminometer (SpectraMax Pro, Molecular Devices).
Synthetic E22P-Aβ 40 dimer24 was used as a standard protein because the E22P-Aβ 40 dimer also containing 
the toxic turn at Glu22 and Asp23 was more stable than the E22P-Aβ 42 dimer. The concentration of the E22P-Aβ 
40 dimer was determined using the Bradford assay (Bio-Rad). The amount of total Aβ 42 in CSF was determined 
by sandwich ELISA with a human β Amyloid ELISA Kit of Aβ 42 [Cat# 27711, human amyloid β (1–42) including 
(X-42)] (IBL) according to the manufacturer’s protocols.
Statistical analysis. All data are presented as mean ± s.e.m. The differences were analyzed with one-way 
analysis of variance (ANOVA) followed by Bonferroni’s test or unpaired Student’s t-test. These tests were imple-
mented within GraphPad Prism software (version 5.0d). p values < 0.05 were considered significant.
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